Navigation Links
JCI early table of contents for Aug. 15, 2013
Date:8/16/2013

e current issue of the Journal of Clinical Investigation, Michael Holtzman and colleagues at the Washington University School of Medicine report that expression of an inflammatory molecule, interleukin-33 (IL-33), is increased in the airways of both a mouse model of viral-induced COPD and humans with COPD. Increased IL-33 was associated with an increase in mucus production, and expression of other COPD-implicated genes. The authors found in their mouse model that expression of the gene encoding IL-33 was localized to a population of lungs cells that were induced in the airway after viral infection. These results lay the groundwork for potential therapeutic strategies aimed at preventing COPD after acute lung infection.

TITLE: Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease

AUTHOR CONTACT: Michael Holtzman
Washington University School of Medicine, St. Louis, MO, USA
Phone: 314-362-8970; Fax: 314-362-9002; E-mail: holtzmanm@wustl.edu

View this article at: http://www.jci.org/articles/view/65570?key=ae7cd696212eb8d494a6


ALSO IN THIS ISSUE

TITLE: Intestinal Epithelial Vitamin D Receptor Signaling Inhibits Experimental Colitis

AUTHOR CONTACT: Yan Chun Li
The University of Chicago, Chicago, IL, USA
Phone: 773-702-2477; Fax: 773-702-2281; E-mail: cyan@medicine.bsd.uchicago.edu

View this article at: http://www.jci.org/articles/view/65842?key=2b9d5961301e6f81b988

TITLE: Fanconi anemia signaling network regulates the spindle assembly checkpoint

AUTHOR CONTACT: D. Wade Clapp
'/>"/>

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Netsmart Clients to Receive Nearly $2 Million in Meaningful Use EHR Incentive Payments
2. Access BridgeGap Ventures to Focus on Early-Stage Therapeutic Opportunities
3. VisionGate Uses $2.6 Million NIH Grant to Achieve Full Automation of Cell-CT™ 3D Imaging System for Early Diagnosis of Cancer
4. Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook
5. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
6. Corporate Venturing and Early-Stage Financing in the Spotlight at BioTrinity
7. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
8. Researchers peek at the early evolution of sex chromosomes
9. Discuss Early Results of the DIAN Trial at CBIs 6th Annual Alzheimers Drug Development Summit
10. Early career distinction: Prestigious award recognizes physicists work in electron dynamics
11. JCI early table of contents for Sept. 4, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was ... Pre-Conference seminar on probiotics in San Diego, CA. , ... conference for health care professionals. This year’s pre-conference seminar was ... in health. Dr. Leyer spoke about the emerging topics and ...
(Date:1/22/2015)...   Cypher Genomics, Inc., the leading genome ... SQNM ), the leading molecular diagnostics company, today ... prenatal tests (NIPT). Through this agreement, Sequenom will ... advance analysis of clinically-relevant fetal sub-chromosomal variants detected ...
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... St. Louis, Missouri (PRWEB) December 23, 2014 ... Swiss biotechnology company, Syngenta, are in the process of being ... consolidated case is In Re: Syngenta AG MIR 162 Corn ... the District of Kansas. , Management of the Syngenta GMO ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... 18 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... authorization (CTA) for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), ... Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome, ... Healthcare Products Regulatory Agency (MHRA). BioMarin expects to initiate ...
... Inc. (OTC Bulletin Board: CSBR), a company engaged in ... data to enhance the value of oncology drugs, reports ... January 31, 2009. Full details of the Company,s ... at www.championsbiotechnology.com . Total revenues for the third ...
... forces), used by ergonomic engineers worldwide, is now more versatile and ... capacities have been doubled to accurately measure up to 300 lbs. ... ... 2009 -- HOGGAN Ergo, Ergonomic Division of HOGGAN Health Industries, ...
Cached Biology Technology:BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 2BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 3BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 4Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 5Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 6HOGGAN Ergo Announces Highly Anticipated Enhancements to the ergoFET Handheld Digital Force Gauge, Greatly Impacting the Field of Ergonomic Research and Application 2HOGGAN Ergo Announces Highly Anticipated Enhancements to the ergoFET Handheld Digital Force Gauge, Greatly Impacting the Field of Ergonomic Research and Application 3
(Date:1/22/2015)... ROBERTS, Washington , January 20, 2015 ... and tech stocks, releases video from the CES 2015 (Consumer ... consultant Apollo Robbins . Apollo shows how ... biometric smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
(Date:1/22/2015)... EyeLock, Inc. , a market leader of iris-based identity authentication ... to the new role of Senior Vice President of Mobile ... mobile platforms and wearable solutions for EyeLock,s technologies. Gerber brings ... semiconductor industry to his role at EyeLock, with expertise in ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ... "The Global Watermarking and Fingerprinting Markets" report ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides an ... fingerprinting markets. Watermarking aims to control and monitor ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2The Global Watermarking and Fingerprinting Markets 2
... Like their human hosts, bacteria need iron to survive and ... obtain iron primarily through the food they eat, bacteria have ... iron. A Syracuse University research team led by Robert ... and Sciences, discovered that some bacteria are equipped with a ...
... to achieve normal levels of blood sugar in ... levels. If this approach succeeds in humans, it ... congenital hyperinsulinism, a rare but potentially devastating genetic ... "There is currently no effective medical treatment ...
... the lowliest bacterium use molecules to communicate. Some chemicals ... still others are used to attract members of the ... have now found a rare kind of signaling molecule ... serves a dual purpose, working as both a population-control ...
Cached Biology News:Syracuse University scientists discover how some bacteria may steal iron from their human hosts 2Syracuse University scientists discover how some bacteria may steal iron from their human hosts 3Treatment corrects severe insulin imbalance in animal studies 2Treatment corrects severe insulin imbalance in animal studies 3Caltech researchers find dual-use sexual attraction and population-control chemicals in nematodes 2Caltech researchers find dual-use sexual attraction and population-control chemicals in nematodes 3
... Automatic High Sensitivity Laboratory Osmometer for both 0.2 and 2.0 mL samples for ... and record keeping. Bar code reading capability with optional scanner. RS-232 port. ... ... ...
MAb to Hu-IFN-Gamma RC2 (CD118), NON-Neutralizing, Clone MMHGR-2 Binds to but does not neutralize human interferon gamma receptor...
Recombinant Rat CINC-2 alpha, CF...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Biology Products: